The potential use of resiniferatoxin, currently in clinical trials for cancer and osteoarthritis pain, as a possible ablating agent of TRPV-1 positive pulmonary pathways in patients with advanced COVID-19 disease, was recommended. Here, TRPV1 is linked to osteoarthritis.